15366-32-2

Basic information

• Product Name: Creatine ethyl ester hydrochloride
• Synonyms: CREATINE ETHYL ESTER HYDROCHLORIDE;CREATINE ETHYL ESTER HCL (P);Creatine ethyl ester hydrochloridel;CREATINE ETHYL ESTER HCL(SH);Ethyl 2-(1-Methylguanidino)acetate hydrochloride;Glycine,N-(aMinoiMinoMethyl)-N-Methyl-, ethyl ester, hydrochloride (1:1);Creatine ethyl ester hydrochloride[3]
• CAS NO: 15366-32-2
• Molecular Formula: C₆H₁₃N₃O₂*ClH
• Molecular Weight: 195.65
• Mol File: 15366-32-2.mol

Chemical Properties

• Melting Point: 162-165°C
• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Creatine ethyl ester hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Creatine ethyl ester hydrochloride(15366-32-2)
• EPA Substance Registry System: Creatine ethyl ester hydrochloride(15366-32-2)

Safety Data

• Hazardous Substances Data: 15366-32-2(Hazardous Substances Data)

Usage

Uses

Used in Sports Nutrition Industry:
Creatine ethyl ester hydrochloride is used as a dietary supplement for athletes and bodybuilders to potentially increase muscle mass, enhance athletic performance, and improve exercise endurance due to its improved absorption and bioavailability compared to other forms of creatine.
Used in Research and Development:
Creatine ethyl ester hydrochloride is utilized in scientific research to investigate its effects on muscle metabolism, athletic performance, and exercise endurance, as well as to explore its safety and long-term effects, given the limited scientific evidence supporting its claims.

InChI:InChI=1/C6H13N3O2.ClH/c1-3-11-5(10)4-9(2)6(7)8;/h3-4H2,1-2H3,(H3,7,8);1H

Upstream product

• 64-17-5 ethanol 
• 57-00-1 Creatinine 
• 60-27-5 creatinine 

Downstream Products

• 60-27-5 creatinine 

Relevant articles and documents

Novel synthetic process for creatine ethyl ester hydrochloride

The invention provides a novel synthetic process for creatine ethyl ester hydrochloride. The novel synthetic process comprises the following synthetic steps: with 4-dimethylaminopyridine (DMAP) as a catalyst and thionyl chloride or carbonyl chloride as a reaction dehydrating agent, allowing creatine to react in absolute ethyl alcohol at a low temperature so as to obtain the creatine ethyl ester hydrochloride. According to the invention, the catalyst effectively improves the rate of an esterification reaction between the creatine and ethyl alcohol, reduces the occurrence of a creatinine side reaction, and improves the purity of the creatine ethyl ester hydrochloride. The overall process provided by the invention basically belongs to a normal-temperature and normla-pressure process, and haslow energy consumption, high creatine conversion rate and high product purity.

Creatine ester anti-inflammatory compounds and formulations

The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue.

Synthesis and biological evaluation of new creatine fatty esters revealed Dodecyl creatine ester as a promising drug candidate for the treatment of the creatine transporter deficiency

The creatine transporter deficiency is a neurological disease caused by impairment of the creatine transporter SLC6A8, resulting in mental retardation associated with a complete absence of creatine within the brain and cellular energy perturbation of neuronal cells. One of the therapeutic hypotheses was to administer lipophilic creatine derivatives which are (1) thought to have better permeability through the cell membrane and (2) would not rely on the activity of SLC6A8 to penetrate the brain. Here, we synthesized creatine fatty esters through original organic chemistry process. A screening on an in vitro rat primary cell-based blood-brain barrier model and on a rat primary neuronal cells model demonstrated interesting properties of these prodrugs to incorporate into endothelial, astroglial, and neuronal cells according to a structure-activity relationship. Dodecyl creatine ester showed then a 20-fold increase in creatine content in pathological human fibroblasts compared with the endogenous creatine content, stating that it could be a promising drug candidate.

Creatine phosphate prodrugs, compositions and uses thereof

Membrane permeable prodrugs of creatine phosphate, pharmaceutical compositions comprising membrane permeable prodrugs of creatine phosphate, and methods of treating diseases such as ischemia, heart failure, and neurodegenerative disorders comprising administering prodrugs of creatine phosphate or pharmaceutical compositions thereof are disclosed.

Labeled creatine ethyl ester hydrochloride

The present invention relates to various radiolabeled creatine ethyl ester hydrochloride compounds. Any carbon, hydrogen or nitrogen atom of the compounds may be radiolabeled using 14C, 13C, 2H, 3H or 15N atoms.

Production of creatine esters using in situ acid production

Methods are provided for the improved production of a creatine ester by in situ production of an acid catalyst.

Creatine ester anti-inflammatory compounds and formulations

The present invention provides a creatine ester anti-inflammatory compound which may be received by animals and then metabolized into a biologically active form of creatine. The biologically active creatine inhibits the production of chemical mediators, released during an inflammatory response, which are important components in the inflammatory response and the inflammation and pain resulting from physical or chemical trauma to cells and tissue.